Skip to main content
Erschienen in: Molecular Imaging and Biology 5/2018

05.03.2018 | Research Article

[18F]Fluorocholine Uptake of Parathyroid Adenoma Is Correlated with Parathyroid Hormone Level

verfasst von: Abdullah A. Alharbi, Fahad M. Alshehri, Abdulrahman A. Albatly, Bert-Ram Sah, Christoph Schmid, Gerhard F. Huber, Martin W. Huellner

Erschienen in: Molecular Imaging and Biology | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of the study was to investigate the relationship between [18F]fluoromethyl-dimethyl-2-hydroxyethylammonium ([18F]FCh) positron emission tomography (PET) parameters, laboratory parameters, and postoperative histopathological results in patients with primary hyperparathyroidism (pHPT) due to parathyroid adenomas.

Procedures

This retrospective study was conducted in 52 patients with biochemically proven pHPT. [18F]FCh-PET parameters (maximum standardized uptake value: SUVmax) in early phase (after 2 min) and late phase (after 50 min), metabolic volume, and adenoma-to-background ratio (ABR), preoperative laboratory results (PTH and serum calcium concentration), and postoperative histopathology (location, size, volume, and weight of adenoma) were assessed. Relationship of PET parameters, laboratory parameters, and histopathological parameters was assessed using the Mann-Whitney U test and Spearman correlation coefficient. MRI characteristics of parathyroid adenomas were also analyzed.

Results

The majority of patients underwent a PET/MR scan, 42 patients (80.7 %); 10 patients (19.3 %) underwent PET/CT. We found a strong positive correlation between late-phase SUVmax and preoperative PTH level (r = 0.768, p < 0.001) and between late-phase ABR and preoperative PTH level (r = 0.680, p < 0.001). The surgical specimen volume was positively correlated with the PET/MR lesion volume (r = 0.659, p < 0.001). No significant association was observed between other [18F]FCh-PET parameters, laboratory parameters, and histopathological findings. Cystic adenomas were larger than non-cystic adenomas (p = 0.048).

Conclusions

[18F]FCh uptake of parathyroid adenomas is strongly correlated with preoperative PTH serum concentration. Therefore, the preoperative PTH level might potentially be able to predict success of [18F]FCh-PET imaging in hyperparathyroidism, with higher lesion-to-background ratios being expected in patients with high PTH. PET/MR is accurate in estimating the volume of parathyroid adenomas.
Literatur
1.
Zurück zum Zitat Fraker DL, Harsono H, Lewis R (2009) Minimally invasive parathyroidectomy: benefits and requirements of localization, diagnosis, and intraoperative PTH monitoring. Long-term results. World J Surg 33:2256–2265CrossRefPubMed Fraker DL, Harsono H, Lewis R (2009) Minimally invasive parathyroidectomy: benefits and requirements of localization, diagnosis, and intraoperative PTH monitoring. Long-term results. World J Surg 33:2256–2265CrossRefPubMed
2.
Zurück zum Zitat Joborn C, Hetta J, Johansson H, Rastad J, Ågren H, Åkerström G, Ljunghall S (1988) Psychiatric morbidity in primary hyperparathyroidism. World J Surg 12:476–480CrossRefPubMed Joborn C, Hetta J, Johansson H, Rastad J, Ågren H, Åkerström G, Ljunghall S (1988) Psychiatric morbidity in primary hyperparathyroidism. World J Surg 12:476–480CrossRefPubMed
3.
Zurück zum Zitat Pasieka JL, Parsons LL (1998) Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperparathyroidism. World J Surg 22:513–519CrossRefPubMed Pasieka JL, Parsons LL (1998) Prospective surgical outcome study of relief of symptoms following surgery in patients with primary hyperparathyroidism. World J Surg 22:513–519CrossRefPubMed
4.
Zurück zum Zitat Yeh MW, Ituarte PH, Zhou HC et al (2013) Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 98:1122–1129CrossRefPubMedPubMedCentral Yeh MW, Ituarte PH, Zhou HC et al (2013) Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 98:1122–1129CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Kelly H, Hamberg L, Hunter G (2014) 4D-CT for preoperative localization of abnormal parathyroid glands in patients with hyperparathyroidism: accuracy and ability to stratify patients by unilateral versus bilateral disease in surgery-naive and re-exploration patients. Am J Neuroradiol 35:176–181CrossRefPubMedPubMedCentral Kelly H, Hamberg L, Hunter G (2014) 4D-CT for preoperative localization of abnormal parathyroid glands in patients with hyperparathyroidism: accuracy and ability to stratify patients by unilateral versus bilateral disease in surgery-naive and re-exploration patients. Am J Neuroradiol 35:176–181CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Quak E, Lheureux S, Reznik Y, Bardet S, Aide N (2013) F18-choline, a novel PET tracer for parathyroid adenoma. J Clin Endocrinol Metab 98:3111–3112CrossRefPubMed Quak E, Lheureux S, Reznik Y, Bardet S, Aide N (2013) F18-choline, a novel PET tracer for parathyroid adenoma. J Clin Endocrinol Metab 98:3111–3112CrossRefPubMed
7.
Zurück zum Zitat Sandqvist P, Nilsson IL, Gryback P, Sanchez-Crespo A, Sundin A (2017) SPECT/CT’s advantage for preoperative localization of small parathyroid adenomas in primary hyperparathyroidism. Clin Nucl Med 42:e109–e114CrossRefPubMed Sandqvist P, Nilsson IL, Gryback P, Sanchez-Crespo A, Sundin A (2017) SPECT/CT’s advantage for preoperative localization of small parathyroid adenomas in primary hyperparathyroidism. Clin Nucl Med 42:e109–e114CrossRefPubMed
8.
Zurück zum Zitat Lezaic L, Rep S, Sever MJ, Kocjan T, Hocevar M, Fettich J (2014) 18F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur J Nucl Med Mol Imaging 41:2083–2089CrossRefPubMed Lezaic L, Rep S, Sever MJ, Kocjan T, Hocevar M, Fettich J (2014) 18F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur J Nucl Med Mol Imaging 41:2083–2089CrossRefPubMed
9.
Zurück zum Zitat Sukan A, Reyhan M, Aydin M, Yapar AF, Sert Y, Canpolat T, Aktas A (2008) Preoperative evaluation of hyperparathyroidism: the role of dual-phase parathyroid scintigraphy and ultrasound imaging. Ann Nucl Med 22:123–131CrossRefPubMed Sukan A, Reyhan M, Aydin M, Yapar AF, Sert Y, Canpolat T, Aktas A (2008) Preoperative evaluation of hyperparathyroidism: the role of dual-phase parathyroid scintigraphy and ultrasound imaging. Ann Nucl Med 22:123–131CrossRefPubMed
10.
Zurück zum Zitat Slater A, Gleeson FV (2005) Increased sensitivity and confidence of SPECT over planar imaging in dual-phase sestamibi for parathyroid adenoma detection. Clin Nucl Med 30:1–3CrossRefPubMed Slater A, Gleeson FV (2005) Increased sensitivity and confidence of SPECT over planar imaging in dual-phase sestamibi for parathyroid adenoma detection. Clin Nucl Med 30:1–3CrossRefPubMed
11.
Zurück zum Zitat Woods AM, Bolster AA, Han S, Poon FW, Colville D, Shand J, Neilly JB (2017) Dual-isotope subtraction SPECT-CT in parathyroid localization. Nucl Med Commun 38:1047–1054CrossRefPubMed Woods AM, Bolster AA, Han S, Poon FW, Colville D, Shand J, Neilly JB (2017) Dual-isotope subtraction SPECT-CT in parathyroid localization. Nucl Med Commun 38:1047–1054CrossRefPubMed
12.
Zurück zum Zitat Huellner MW, Aberle S, Sah BR, Veit-Haibach P, Bonani M, Schmid C, Steinert H (2016) Visualization of parathyroid hyperplasia using 18F-fluorocholine PET/MR in a patient with secondary hyperparathyroidism. Clin Nucl Med 41:e159–e161CrossRefPubMed Huellner MW, Aberle S, Sah BR, Veit-Haibach P, Bonani M, Schmid C, Steinert H (2016) Visualization of parathyroid hyperplasia using 18F-fluorocholine PET/MR in a patient with secondary hyperparathyroidism. Clin Nucl Med 41:e159–e161CrossRefPubMed
14.
Zurück zum Zitat Hocevar M, Lezaic L, Rep S, Zaletel K, Kocjan T, Sever MJ, Zgajnar J, Peric B (2017) Focused parathyroidectomy without intraoperative parathormone testing is safe after pre-operative localization with 18F-Fluorocholine PET/CT. Eur J Surg Oncol 43:133–137CrossRefPubMed Hocevar M, Lezaic L, Rep S, Zaletel K, Kocjan T, Sever MJ, Zgajnar J, Peric B (2017) Focused parathyroidectomy without intraoperative parathormone testing is safe after pre-operative localization with 18F-Fluorocholine PET/CT. Eur J Surg Oncol 43:133–137CrossRefPubMed
15.
Zurück zum Zitat Kluijfhout WP, Vorselaars WM, van den Berk SA et al (2016) Fluorine-18 fluorocholine PET-CT localizes hyperparathyroidism in patients with inconclusive conventional imaging: a multicenter study from the Netherlands. Nucl Med Commun 37:1246–1252CrossRefPubMed Kluijfhout WP, Vorselaars WM, van den Berk SA et al (2016) Fluorine-18 fluorocholine PET-CT localizes hyperparathyroidism in patients with inconclusive conventional imaging: a multicenter study from the Netherlands. Nucl Med Commun 37:1246–1252CrossRefPubMed
16.
Zurück zum Zitat Michaud L, Balogova S, Burgess A et al (2015) A pilot comparison of 18F-fluorocholine PET/CT, ultrasonography and 123I/99mTc-sestaMIBI dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: influence of thyroid anomalies. Medicine 94:e1701CrossRefPubMedPubMedCentral Michaud L, Balogova S, Burgess A et al (2015) A pilot comparison of 18F-fluorocholine PET/CT, ultrasonography and 123I/99mTc-sestaMIBI dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: influence of thyroid anomalies. Medicine 94:e1701CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Thanseer N, Bhadada SK, Sood A et al (2017) Comparative effectiveness of ultrasonography, 99mTc-sestamibi, and 18F-fluorocholine PET/CT in detecting parathyroid adenomas in patients with primary hyperparathyroidism. Clin Nucl Med 42:e491-e497CrossRefPubMed Thanseer N, Bhadada SK, Sood A et al (2017) Comparative effectiveness of ultrasonography, 99mTc-sestamibi, and 18F-fluorocholine PET/CT in detecting parathyroid adenomas in patients with primary hyperparathyroidism. Clin Nucl Med 42:e491-e497CrossRefPubMed
18.
Zurück zum Zitat DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE (2002) Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 43:92–96PubMed DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE (2002) Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 43:92–96PubMed
19.
Zurück zum Zitat Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, Cozzarini C, di Muzio N, Rigatti P, Fazio F, Messa C (2010) Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 37:301–309CrossRefPubMed Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, Cozzarini C, di Muzio N, Rigatti P, Fazio F, Messa C (2010) Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 37:301–309CrossRefPubMed
20.
Zurück zum Zitat Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, Mancini M (2008) Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 113:895–904CrossRefPubMed Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, Mancini M (2008) Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 113:895–904CrossRefPubMed
21.
Zurück zum Zitat Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN (2006) Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 47:262–269PubMed Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN (2006) Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 47:262–269PubMed
22.
Zurück zum Zitat Oprea-Lager DE, Vincent AD, van Moorselaar RJ et al (2012) Dual-phase PET-CT to differentiate [18F]fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer. PLoS One 7:–e48430 Oprea-Lager DE, Vincent AD, van Moorselaar RJ et al (2012) Dual-phase PET-CT to differentiate [18F]fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer. PLoS One 7:–e48430
23.
Zurück zum Zitat Rep S, Lezaic L, Kocjan T, Pfeifer M, Sever MJ, Simoncic U, Tomse P, Hocevar M (2015) Optimal scan time for evaluation of parathyroid adenoma with [18F]-fluorocholine PET/CT. Radiol Oncol 49:327–333CrossRefPubMedPubMedCentral Rep S, Lezaic L, Kocjan T, Pfeifer M, Sever MJ, Simoncic U, Tomse P, Hocevar M (2015) Optimal scan time for evaluation of parathyroid adenoma with [18F]-fluorocholine PET/CT. Radiol Oncol 49:327–333CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Vellani C, Hodolic M, Chytiris S, Trifiro G, Rubello D, Colletti PM (2017) Early and delayed 18F-FCH PET/CT imaging in parathyroid adenomas. Clin Nucl Med 42:143–144CrossRefPubMed Vellani C, Hodolic M, Chytiris S, Trifiro G, Rubello D, Colletti PM (2017) Early and delayed 18F-FCH PET/CT imaging in parathyroid adenomas. Clin Nucl Med 42:143–144CrossRefPubMed
25.
Zurück zum Zitat Kadrmas DJ, Casey ME, Conti M, Jakoby BW, Lois C, Townsend DW (2009) Impact of time-of-flight on PET tumor detection. J Nucl Med 50:1315–1323CrossRefPubMed Kadrmas DJ, Casey ME, Conti M, Jakoby BW, Lois C, Townsend DW (2009) Impact of time-of-flight on PET tumor detection. J Nucl Med 50:1315–1323CrossRefPubMed
27.
Zurück zum Zitat Surti S, Karp S, Popescu LM, Daube-Witherspoon E, Werner M (2006) Investigation of time-of-flight benefit for fully 3-DPET. IEEE Trans Med Imaging 25:529–538CrossRefPubMed Surti S, Karp S, Popescu LM, Daube-Witherspoon E, Werner M (2006) Investigation of time-of-flight benefit for fully 3-DPET. IEEE Trans Med Imaging 25:529–538CrossRefPubMed
28.
Zurück zum Zitat Karp JS, Surti S, Daube-Witherspoon ME, Muehllehner G (2008) Benefit of time-of-flight in PET: experimental and clinical results. J Nucl Med 49:462–470CrossRefPubMed Karp JS, Surti S, Daube-Witherspoon ME, Muehllehner G (2008) Benefit of time-of-flight in PET: experimental and clinical results. J Nucl Med 49:462–470CrossRefPubMed
30.
Zurück zum Zitat Queiroz MA, Delso G, Wollenweber S, Deller T, Zeimpekis K, Huellner M, de Galiza Barbosa F, von Schulthess G, Veit-Haibach P (2015) Dose optimization in TOF-PET/MR compared to TOF-PET/CT. PLoS One 10:e0128842CrossRefPubMedPubMedCentral Queiroz MA, Delso G, Wollenweber S, Deller T, Zeimpekis K, Huellner M, de Galiza Barbosa F, von Schulthess G, Veit-Haibach P (2015) Dose optimization in TOF-PET/MR compared to TOF-PET/CT. PLoS One 10:e0128842CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Sekine T, Delso G, Zeimpekis KG, et al (2017) Reduction of 18F-FDG dose in clinical PET/MR imaging by using silicon photomultiplier detectors. Radiology:162305 Sekine T, Delso G, Zeimpekis KG, et al (2017) Reduction of 18F-FDG dose in clinical PET/MR imaging by using silicon photomultiplier detectors. Radiology:162305
32.
Zurück zum Zitat Yousem D (1996) Parathyroid and thyroid imaging. Neuroimaging Clin N Am 6:435–459PubMed Yousem D (1996) Parathyroid and thyroid imaging. Neuroimaging Clin N Am 6:435–459PubMed
33.
Zurück zum Zitat Nael K, Hur J, Bauer A, Khan R, Sepahdari A, Inampudi R, Guerrero M (2015) Dynamic 4D MRI for characterization of parathyroid adenomas: multiparametric analysis. Am J Neuroradiol 36:2147–2152CrossRefPubMedPubMedCentral Nael K, Hur J, Bauer A, Khan R, Sepahdari A, Inampudi R, Guerrero M (2015) Dynamic 4D MRI for characterization of parathyroid adenomas: multiparametric analysis. Am J Neuroradiol 36:2147–2152CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat McCoy KL, Yim JH, Zuckerbraun BS, Ogilvie JB, Peel RL, Carty SE (2009) Cystic parathyroid lesions: functional and nonfunctional parathyroid cysts. Arch Surg 144:52–56CrossRefPubMed McCoy KL, Yim JH, Zuckerbraun BS, Ogilvie JB, Peel RL, Carty SE (2009) Cystic parathyroid lesions: functional and nonfunctional parathyroid cysts. Arch Surg 144:52–56CrossRefPubMed
35.
Zurück zum Zitat Randel SB, Gooding G, Clark OH, Stein R, Winkler B (1987) Parathyroid variants: US evaluation. Radiology 165:191–194CrossRefPubMed Randel SB, Gooding G, Clark OH, Stein R, Winkler B (1987) Parathyroid variants: US evaluation. Radiology 165:191–194CrossRefPubMed
36.
Zurück zum Zitat Johnson NA, Yip L, Tublin ME (2010) Cystic parathyroid adenoma: sonographic features and correlation with 99mTc-sestamibi SPECT findings. Am Jo Roentgenol 195:1385–1390CrossRef Johnson NA, Yip L, Tublin ME (2010) Cystic parathyroid adenoma: sonographic features and correlation with 99mTc-sestamibi SPECT findings. Am Jo Roentgenol 195:1385–1390CrossRef
37.
Zurück zum Zitat Parfitt MA, Rao DS, Kleerekoper M (1991) Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: clinical course and considerations bearing on the need for surgical intervention. J Bone Miner Res 6:S97–S101CrossRefPubMed Parfitt MA, Rao DS, Kleerekoper M (1991) Asymptomatic primary hyperparathyroidism discovered by multichannel biochemical screening: clinical course and considerations bearing on the need for surgical intervention. J Bone Miner Res 6:S97–S101CrossRefPubMed
38.
Zurück zum Zitat Eiber M, Rauscher I, Souvatzoglou M et al (2017) Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging:1–10 Eiber M, Rauscher I, Souvatzoglou M et al (2017) Prospective head-to-head comparison of 11C-choline-PET/MR and 11C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging:1–10
39.
Zurück zum Zitat Souvatzoglou M, Eiber M, Takei T, Fürst S, Maurer T, Gaertner F, Geinitz H, Drzezga A, Ziegler S, Nekolla SG, Rummeny EJ, Schwaiger M, Beer AJ (2013) Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging 40:1486–1499CrossRefPubMed Souvatzoglou M, Eiber M, Takei T, Fürst S, Maurer T, Gaertner F, Geinitz H, Drzezga A, Ziegler S, Nekolla SG, Rummeny EJ, Schwaiger M, Beer AJ (2013) Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging 40:1486–1499CrossRefPubMed
40.
Zurück zum Zitat Iagaru A, Mittra E, Minamimoto R, Jamali M, Levin C, Quon A, Gold G, Herfkens R, Vasanawala S, Gambhir SS, Zaharchuk G (2015) Simultaneous whole-body time-of-flight 18F-FDG PET/MRI: a pilot study comparing SUVmax with PET/CT and assessment of MR image quality. Clin Nucl Med 40:1–8CrossRefPubMedPubMedCentral Iagaru A, Mittra E, Minamimoto R, Jamali M, Levin C, Quon A, Gold G, Herfkens R, Vasanawala S, Gambhir SS, Zaharchuk G (2015) Simultaneous whole-body time-of-flight 18F-FDG PET/MRI: a pilot study comparing SUVmax with PET/CT and assessment of MR image quality. Clin Nucl Med 40:1–8CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Jolepalem P, Rydberg JN, Wong CO (2013) Improvement of hepatic lesion characterization by 18F-FDG PET/CT with the use of the lesion to background liver activity ratio. Clin Nucl Med 38:869–873CrossRefPubMed Jolepalem P, Rydberg JN, Wong CO (2013) Improvement of hepatic lesion characterization by 18F-FDG PET/CT with the use of the lesion to background liver activity ratio. Clin Nucl Med 38:869–873CrossRefPubMed
42.
Zurück zum Zitat Jolepalem P, Flynt L, Rydberg JN, Wong CY (2014) Implications of ambient glucose variation on the target-to-background ratio of hepatic tumors by 18FDG-PET imaging. J Clin Imaging Sci 4:39CrossRefPubMedPubMedCentral Jolepalem P, Flynt L, Rydberg JN, Wong CY (2014) Implications of ambient glucose variation on the target-to-background ratio of hepatic tumors by 18FDG-PET imaging. J Clin Imaging Sci 4:39CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Teoh EJ, McGowan DR, Macpherson RE, Bradley KM, Gleeson FV (2015) Phantom and clinical evaluation of the Bayesian penalized likelihood reconstruction algorithm Q.Clear on an LYSO PET/CT system. J Nucl Med 56:1447–1452CrossRefPubMed Teoh EJ, McGowan DR, Macpherson RE, Bradley KM, Gleeson FV (2015) Phantom and clinical evaluation of the Bayesian penalized likelihood reconstruction algorithm Q.Clear on an LYSO PET/CT system. J Nucl Med 56:1447–1452CrossRefPubMed
Metadaten
Titel
[18F]Fluorocholine Uptake of Parathyroid Adenoma Is Correlated with Parathyroid Hormone Level
verfasst von
Abdullah A. Alharbi
Fahad M. Alshehri
Abdulrahman A. Albatly
Bert-Ram Sah
Christoph Schmid
Gerhard F. Huber
Martin W. Huellner
Publikationsdatum
05.03.2018
Verlag
Springer International Publishing
Erschienen in
Molecular Imaging and Biology / Ausgabe 5/2018
Print ISSN: 1536-1632
Elektronische ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-018-1179-x

Weitere Artikel der Ausgabe 5/2018

Molecular Imaging and Biology 5/2018 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.